

COVID-19, Mpox, and Travel Advisories Situational Report in the ASEAN Region

-ASEAN BioDiaspora Virtual Center (ABVC)

February 24, 2023 | Issue No. 452



ASSOCIATION OF SOUTHEAST ASIAN NATIONS



ASEAN BIODIASPORA VIRTUAL CENTER (ABVC)





GLOBAL PARTNERS















Table of Contents

COVID-19	1
Highlights and Situation Overview	1
<u>Global Update</u>	1
<u>Regional Update</u>	1
<u>Research Update</u>	2
ASEAN Travel Advisories	5
COVID-19 Cases and Deaths Table	7
COVID-19 Cases in ASEAN Region Table	7
<u>COVID-19 Cases in Asia-Pacific Region Table</u>	
Epi curve Among ASEAN Countries	
Vaccination Status in ASEAN	0
ASEAN Outlook Assessment	1
Special Report on Notable Diseases	
<u>Avian Influenza H5N1</u>	2
Мрох1	3
Mpox Cases Global Map	3
Mpox Daily Trend Globally	4
Highlights and Situation Overview	5
Mpox Cases in ASEAN Region Table	
Mpox Cases in Asia-Pacific Region Table	
Top 5 Countries with Most Mpox Cases Globally	5
Mpox Cases per Region	
Research Update	
References	7



COVID-19: Highlights and Situation Overview

Global Update

- Worldwide, there have been over 664 million cases and over 6 million deaths attributed to COVID-19.
- The World Health Organization (WHO) reported in its latest pandemic update that the monthly averages for new COVID-19 cases and deaths continue to steadily decline. COVID-19 cases were down by 89% compared to 28 days ago, with the declines seen across all six world regions. Deaths were likewise down by 62% during the same period, with declines seen in all world regions except for the Eastern Mediterranean. The five countries reporting the most cases are the United States, Japan, China, South Korea, and Germany. All of them, however, reported drops in cases over the past month. Meanwhile, according to the WHO's variant update, BA.5 Omicron subvariant levels continue to decline, offset by rises in recombinant subvariants, with XBB.1.5 the most common one at 29.6% and up from 26.1% the previous week. The XBF, which was recently added as a subvariant under WHO monitoring which makes up 1.8% of sequences, up from 1.2% the week before. [Full report]
- China halted some classes amid school COVID-19 clusters and cases caused by other pathogens ranging from flu to the norovirus. Hangzhou's local education authorities suspended their class for four days starting this week after ten second-graders in the same classroom tested positive for COVID-19 on rapid antigen tests. Shanghai likewise suspended in-person teaching in an elementary school class after four students were diagnosed with the flu and others developed similar symptoms. Flu cases and subsequent class suspensions were also reported in other schools across Zhejiang province, Chinese capital Beijing and nearby city Tianjin.
- **Taiwan**'s Central Epidemic Command Center (CECC) said on February 23 (Thursday) that it would run a COVID-19 vaccination campaign from March 6 to April 30 to increase the inoculation rate ahead of a greater easing of pandemic measures. According to the CECC, those who have not received at least two shots of a COVID-19 vaccine, as well as those aged six and older who have not had a bivalent vaccine booster shot, are encouraged to take advantage of the offerings. Those who have had COVID-19, however, should wait at least 84 days from the time of a negative test to receive a vaccine, adding that 84 days should also pass after a second dose before receiving a booster shot. According to Deputy Minister of Health and Welfare Victor Wang, who heads the CECC, COVID-19 vaccines will continue to be publicly funded this year.

Regional Update

• **Philippines:** The Food and Drug Administration (FDA) has formed a task force to simplify the process of developing safe and effective COVID-19 medications for the Philippine market.⁹ FDA Director General Samuel Zacate stated in a statement that the specialist team, dubbed "Task Force Fleming," will streamline the approval and review of COVID-19 medications without sacrificing efficacy, quality, or safety.⁹ Task Force Fleming was named after Dr. Alexander Fleming, a British physician best known for accidently finding the first efficient antibiotic medication penicillin, which substantially aided in the fight against disease.⁹ According to Zarate, the group will also assist the government in shifting its attention from COVID-19 crisis management to focusing on a more robust recovery of the country's economy.⁹ [Full article]



Research Update (Published and peer-reviewed studies)

- This cohort study, Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared with Influenza Infection in Switzerland, compared the inhospital outcomes of patients hospitalized with the SARS-CoV-2 Omicron variant with patients with influenza based on a national COVID-19 and influenza registry.¹ Hospitalized patients aged 18 years and older with community-acquired SARSCoV-2 Omicron variant infection who were admitted between January 15 and March 15, 2022 (when B.1.1.529 Omicron predominance was >95%), and hospitalized patients with influenza A or B infection from January 1, 2018, to March 15, 2022, the study was conducted at 15 hospitals in Switzerland.¹ Of 5,212 patients included from 15 hospitals, 3,066 (58.8%) had SARS-CoV-2 Omicron variant infection in 14 centers and 2,146 patients (41.2%) had influenza A or B in 14 centers.¹ Patients with the SARS-CoV-2 Omicron variant were younger (median [IQR] age, 71 [53-82] years) than those with influenza (median [IQR] age, 74 [59-83] years; P < .001).¹ Overall, 214 patients with the SARS-CoV-2 Omicron variant (7.0%) died during hospitalization vs 95 patients with influenza (4.4%; P < .001).¹ The final adjusted subdistribution hazard ratio (sdHR) for in-hospital death for SARS-CoV-2 Omicron variant vs influenza was 1.54 (95% CI, 1.18-2.01; P = .002).¹ Overall, 250 patients with the SARS-CoV-2 Omicron variant (8.6%) vs 169 patients with influenza (8.3%) were admitted to the ICU (P = .79).¹ After adjustment, the SARS-CoV-2 Omicron variant was not significantly associated with increased ICU admission vs influenza (sdHR, 1.08; 95% CI, 0.88-1.32; P = .50).¹ These findings suggest that, despite virus evolution and improved management strategies, patients with the SARS-CoV-2 Omicron variant had a higher risk of in-hospital mortality than those with influenza.¹ [Full text]
- Beginning December 6, 2021, all international air passengers boarding flights to the United States were required to show either a negative result from a SARS-CoV-2 viral test taken ≤1 day before departure or proof of recovery from COVID-19 within the preceding 90 days.² As of June 12, 2022, predeparture testing was no longer mandatory but remained recommended by CDC.² Various modeling studies have estimated that predeparture testing the day before or the day of air travel reduces transmission or importation of SARS-CoV-2 by 31%–76%.² In this study, *Effect of Predeparture Testing on* Postarrival SARS-CoV-2-Positive Test Results Among International Travelers - CDC Traveler-Based Genomic Surveillance Program, Four U.S. Airports, March-September 2022, post arrival SARS-CoV-2 pooled testing data from CDC's Traveler-based Genomic Surveillance program were used to compare SARS-CoV-2 test results among volunteer travelers arriving at four U.S. airports during two 12-week periods: March 20-June 11, 2022, when predeparture testing was required, and June 12-September 3, 2022, when predeparture testing was not required.² Among 3,049 pooled (28,056 individual) samples collected during March 20-September 3, 2022, the predeparture testing requirement was associated with 52% lower post arrival SARS-CoV-2 positivity.² Predeparture testing can reduce SARS-CoV-2 transmission risk during or after travel by reducing the number of infectious travelers.² These results can help guide decisions for future outbreaks.² [Full text]
- The SARS-CoV-2 Omicron XBB.1.5 variant, a recombinant variant of Omicron BA.2.75 and BA.2.10, was first detected in New York City (NYC) in October 2022.³ As of January 7, 2023, XBB.1.5 was the predominant variant in NYC, accounting for 81% of sequenced specimens; at that time, only 26% of sequenced specimens nationwide were XBB.1.5.³ In December 2022, only 5% of sequenced genomes in the rest of New York were XBB.1.5, suggesting that NYC was likely the epicenter of XBB.1.5's emergence in the United States.³ The World Health Organization has noted that XBB.1.5 does not carry any mutation known to be associated with a potential change in severity, however, there are currently limited data available about disease severity in human populations.³ This study, Epidemiologic Characteristics of SARS-CoV-2 Recombinant Variant XBB.1.5—New



York City, November 1, 2022-January 4, 2023, described SARS-CoV-2 Omicron XBB.1.5 variant cases as to characteristics and outcomes.³ During November–December 2022, the percentage of sequenced SARS-CoV-2 isolates in NYC identified as XBB.1.5 increased eightfold, from 8% to 72%.³ Compared with patients infected with BQ.1 (p<0.0001) those with XBB.1.5 infections tended to be younger (median age = 41 years [XBB.1.5] versus 44 years [BQ.1]), Hispanic or Latino or non-Hispanic Black or African American (Black) (68.1% versus 61.5%), and residents of the Bronx, Brooklyn, or Queens (82.6% versus 76.1%); a higher percentage lived in high- or very high-poverty neighborhoods (43.2% versus 41.9%).³ The percentage who had received a primary COVID-19 vaccination series and ≥ 1 dose of monovalent vaccine booster was lower among patients with XBB.1.5 infections (41.1%) than among those with BQ.1 infections (46.0%).³ The percentages of XBB.1.5 and BQ.1 patients whose specimen was collected \geq 90 days after a previous collection of a specimen with a SARS-CoV-2-positive test result, which could suggest possible reinfection, were similar (25.2% [XBB.1.5]; 25.4% [BQ.1]).³ No difference in the proportion of patients hospitalized or those who died was observed, suggesting no significant difference in disease severity.³ [Full text]

- Because SARS-CoV-2 can be detected in feces and urine of some infected persons, wastewater surveillance in airports and on aircraft has been proposed by the global public health community as a low-cost mechanism to monitor SARS-CoV-2 variants entering the United States.⁴ Sampling wastewater directly from aircraft can be used to link SARS-CoV-2 lineage data with flight origin countries without active engagement of travelers.⁴ This study, Aircraft Wastewater Surveillance for Early Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City, August-September 2022, evaluated the feasibility of SARS-CoV-2 variant detection in aircraft wastewater from incoming international flights.⁴ Aircraft wastewater samples were collected from selected flights from the United Kingdom, Netherlands, and France arriving at John F. Kennedy International Airport in New York City. Wastewater (approximately 0.25 gal [1 L]) was collected from each plane during normal maintenance using a device that attaches to the lavatory service panel port and the lavatory service truck hose.⁴ During August 1–September 9, 2022, one sample was collected from each of 88 flights.⁴ Eighty samples were tested for SARS-CoV-2.4 Overall, 65 samples (81%) were positive; the percentage that were positive was similar among the three flight origin countries sampled (Netherlands: 81% [22 of 27]; France: 81% [22 of 27]; and United Kingdom: 81% [21 of 26]).⁴ Twenty seven SARS-CoV-2 genomes were detected in 25 wastewater samples; sequencing quality control criteria were not met for the remaining 40 positive samples.⁴ All identified genomes were Omicron sublineages (United Kingdom: 12 BA.5 and one BA.4.6; France: eight BA.5; and Netherlands: five BA.5 and one BA.2.75).⁴ In each of 23 samples, single SARS-CoV-2 genomes were identified and assigned to the BA.5 (21), BA.4.6 (one), and BA.2.75 (one) sublineages.⁴ In each of two additional samples, two distinct SARS-CoV-2 genomes were identified and assigned to different BA.5 sublineages.⁴ The SARS-CoV-2 genomes identified in aircraft lavatory wastewater were consistent with Western European sequences uploaded to the Global Initiative on Sharing Avian Influenza Data (GISAID) at the time (approximately 90% BA.5).⁴ This investigation demonstrated the feasibility of aircraft wastewater surveillance as a lowresource approach compared with individual testing to monitor SARS-CoV-2 variants without direct traveler involvement or disruption to airport operations.⁴ [Full text]
- In the study Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5–17-year-old children in the United States, researchers evaluated the COVID-19 vaccine-associated composite serious adverse events following immunization (sAEFI) among five- to 17-year-old children in the United States to determine the complex reported risk associated with vaccination.⁵ During the study period, 467,890,599 SARS-CoV-2 vaccines were provided to five- to 65-year-old U.S. residents, with 180,581,278 who had received more than two vaccine doses.⁵ A total of 177,679 AEFI



were documented by the vaccine adverse event reporting system (VAERS), 18% of which were serious.⁵ The rates of emergency department visits per 100,000 vaccinees were 2.6 among individuals aged five to 11 years, 18 among those aged 12 to 17 years, and 34 among those aged 18 to 65 years.⁵ The corresponding rates of hospital admissions among every 100,000 vaccinees were 1.1, 6.8, and 8.2, respectively, and of fatal events per 100,000 vaccinees were 0.1, 1.2, and 3.0, respectively.⁵ Mortality rates among the corresponding groups for every 100,000 vaccinees were 0.03, 0.1, and 0.8, respectively.⁵ The overall sAEFI rates among children receiving BNT-162b vaccines were very low.⁵ In comparison to adults, those between 12 and 17 years of age had greater rates of hospitalizations and emergency department visits.⁵ In conclusion, the rates of reported sAEFIs among individuals between five and 17 years of age were significantly lower than among those reported in individuals between 18 and 65 years of age, thus supporting the administration of COVID-19 vaccines to children.⁵ [Full text]

ASEAN Travel Advisories (new update/s)

as of 24 February 2023

ASEAN Country	Published	Foreign travelers allowed	COVID-19 vaccination requirement	Required COVID-19 testing for fully vaccinated	Required COVID-19 testing for NOT fully vaccinated	Quarantine upon arrival	Health insurance requirement	Arrival health declaration/ registration/ documents
Brunei Darussalam	December 1, 2022	Yes	No	No	No	No	No	No
Cambodia	October 6, 2022	Yes	No	No	No	No	No	No
Indonesia	December 7, 2022	Yes	Yes – fully vaccinated* certificate for 18 years old and above.	No, but may be subject to RT-PCR upon arrival	Foreign travelers who are not fully vaccinated may not be allowed to enter Indonesia or may be subjected to RT-PCR test upon arrival	No	No	Traveler is required to download and register at <u>PeduliLindungi app</u> before departure.
Laos	December 29, 2022	Yes	No	No	No	No	No	No
Malaysia	August 2, 2022	Yes	No	No	No	No	No	No
Myanmar	December 1, 2022	Yes	Yes – fully vaccinated* certificate for 12 years old and above.	Yes – printed negative COVID-19 antigen test result for 12 years old and above taken within 48 hours before arrival.	Foreign travelers who are not fully vaccinated are not allowed to enter or transit Myanmar.	No	Required to obtain <u>Myanmar</u> Insurance	No
Philippines	December 1, 2022	Yes	Yes – fully vaccinated* with booster dose certificate for 15 years old and above.	No	Yes – COVID-19 rapid antigen test taken at most 24 hours before departure or subject to a rapid test upon arrival.	No	No	Traveler is required to download and register at <u>E-arrival card</u> at most 3 days before departure for those without visa.
Singapore	February 13, 2023	Yes	No	No	No	No	No	No
Thailand	January 14, 2023	Yes	No	No	No	No	Foreign passengers arriving from China or India	No



							must have insurance to cover COVID- 19 expenses at least US\$10,000.	
Vietnam	May 16, 2022	Yes	No	No	No	No	No	No

Reference: <u>IATA Travel Centre</u>
*Fully vaccinated – at least 14 or 15 days from 2nd dose for two-dose vaccine or 14 or 15 days from a single dose vaccine upon arrival.

COVID-19 Cases and Deaths as of 23 February 2023

- As of 23 February 2023 (1PM, GMT+7), worldwide, there were 664,596,105 confirmed cases, including 6,776,790 deaths. Globally, Case Fatality Rate (CFR) was 1.2%.
- 35,592,313 confirmed cases of COVID-19 have been reported in the ASEAN Region.
- The Case Fatality Rate in the **ASEAN** Region is range between **0.1 to 3.1%**.

COVID-19 cases in ASEAN region

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN	Brunei Darussalam	10 Mar 20	23-Feb-23	276,825	-	225	-	63,890	450,404	445,929	338,987	99.3
REGION	Cambodia	27 Jan 20	23-Feb-23	138,712	-	3,056	-	841	15,244,858	14,609,937	10,433,215	87.1
	Indonesia	02 Mar 20	23-Feb-23	6,734,606	-	160,892	-	2,489	203,657,535	172,693,321	67,952,274	62.7
	Lao PDR	24 Mar 20	23-Feb-23	218,012	-	758	-	3,041	5,888,649	5,222,417		69.4
	Malaysia	25 Jan 20	23-Feb-23	5,041,587	229	36,957	-	15,780	28,125,245	27,536,657	17,056,957	81.1
	Myanmar	23 Mar 20	23-Feb-23	633,901	-	19,490	-	1,173	34,777,314	27,545,329	2,227,351	50.8
	Philippines	30 Jan 20	23-Feb-23	4,075,757	146	66,051	12	3,770	78,369,243	73,937,435	21,341,197	64.0
	Singapore	23 Jan 20	23-Feb-23	2,218,623	-	1,722	-	38,899	5,161,990	5,120,768	4,440,289	90.8
	Thailand	13 Jan 20	23-Feb-23	4,727,831	-	33,902	-	6,790	57,005,497	53,486,086	32,143,431	74.6
	Vietnam	23 Jan 20	23-Feb-23	11,526,834	-	43,186	-	11,950	90,450,881	85,848,363	57,452,750	87.4
		ASI	EAN COUNTRIES	35,592,688	375	366,239	12	148,622	519,131,616	466,446,242	213,386,451	

COVID-19 cases in Asia-Pacific region

REGION	COUNTRY/ TERRITORY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASIA-	Afghanistan	24-Feb-20	21-Feb-23	209,181	-	7,896	-	550	11,606,705	10,894,509		26.5
PACIFIC	Australia	25-Jan-20	22-Feb-23	11,352,771	17,851	19,265	202	44,260	22,236,871	21,655,312	19,762,423	82.7
REGION	Bangladesh	08-Mar-20	18-Feb-23	2,037,738	-	29,445	-	1,250	150,629,515	131,182,263	65,897,152	76.6
	Bhutan	05-Mar-20	14-Feb-23	62,611	-	21	-	8,205	699,116	677,669	634,641	86.6
	People's Republic of China*		23-Feb-23	13,343,824	-	36,446	-	81,427	1,339,608,531	1,304,575,996	214,031,616	89.7
	Cook Islands	17-Feb-22	17-Feb-23	7,025	-	2	-	32,846	15,084	14,715	10,209	86.4
	Fiji	18-Mar-20	17-Feb-23	68,876	-	883	-	7,739	711,686	640,712	170,632	68.9
	French Polynesia	12-Mar-20	04-Jan-23	77,957	-	649	-	27,913	190,765	186,059	112,237	60.8
	Guam	15-Mar-20	20-Feb-23	60,947	-	419	-	36,431	158,611	144,042		85.5
	India	30-Jan-20	22-Feb-23	44,685,257	125	530,762	1	3,270	1,027,279,394	951,464,506	224,093,416	67.1
	Japan	16-Jan-20	19-Oct-22	21,858,528	-	46,014	-	17,312	104,612,252	103,222,040	169,610,887	83.3



Kiribati	25-Jan-22	15-Feb-23	5,012	-	18	-	4,262	96,184	73,888	23,419	56.3
Maldives	07-Mar-20	21-Feb-23	185,729	-	311	-	34,980	399,151	385,081	167,187	73.5
Marshall Islands	26-Oct-20	17-Feb-23	15,598	-	17	-	26,531	43,310	34,694		44.6
Micronesia	11-Jan-21	23-Jan-23	23,671	-	60	-	20,798	84,729	71,253		69.6
Mongolia	10-Mar-20	17-Feb-23	1,007,895	-	2,179	-	31,251	2,272,965	2,175,617	1,044,337	64.0
Nepal	24-Jan-20	20-Feb-23	1,001,135	-	12,020	-	3,499	27,678,479	24,159,118	8,951,403	79.
New Caledonia	17-Mar-20	21-Feb-23	79,871	-	314	-	27,752	192,229	184,660	101,849	63.
New Zealand	28-Feb-20	20-Feb-23	2,207,775	-	3,864	-	44,901	4,300,097	4,138,926	3,523,903	79.
Niue	03-Sep-21	21-Feb-23	783	-	-	-	36,150	1,636	1,634	1,224	83.
Northern Mariana Islands	28-Mar-20	17-Feb-23	13,605	-	41	-	23,778	46,567	43,873		84.
Pakistan	26-Feb-20	21-Feb-23	1,576,737	-	30,641	-	728	154,665,740	131,368,973	49,551,181	55
Palau	31-May-21	14-Feb-23	5,988	-	9	-	33,252	20,750	18,497		85
Papua New Guinea	21-Mar-20	15-Feb-23	46,792	-	670	-	533	369,998	310,717	32,384	3.
Samoa	18-Nov-20	19-Feb-23	16,594	-	29	-	8,419	191,171	177,741	79,360	79
Solomon Islands	03-Oct-20	24-Nov-22	24,575	-	153	-	3,669	343,821	254,352	27,783	35
Republic of Korea**	20-Jan-20	22-Feb-23	30,458,857	13,082	33,893	20	58,904	44,867,046	44,448,105	41,325,954	85
Sri Lanka	27-Jan-20	22-Feb-23	672,024	1	16,829	-	3,082	17,143,761	14,752,827	8,220,002	67
Timor Leste	21-Mar-20	16-Feb-23	23,418	-	138	-	1,811	878,845	790,466	315,249	58
Tonga	05-Nov-21	17-Feb-23	16,801	-	13	-	16,078	91,949	77,464	38,331	72
Türkiye	10-Mar-20	12-Dec-22	17,041,315	-	101,487	-	20,426	57,941,051	53,176,961	41,425,329	62
Vanuatu	11-Nov-20	06-Jan-23	12,014	-	14	-	4,006	144,824	131,697	16,996	40.
Wallis et Futuna	17-Oct-20	31-Dec-22	3,427	-	7	-	21,385	7,150	6,803	3,766	58.
		ASIA PACIFIC	148,204,331	31,059	874,509	223	687,400	2,969,529,983	2,801,441,170	849,172,870	


*Includes cases from Hong Kong (SAR), Macau (SAR), and Taiwan (Province of China) ** Republic of Korea – South Korea

• 480,799,086 confirmed cases of COVID-19 have been reported in other 4 regions (other than ASEAN and Asia-Pacific countries):

REGION	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED
AFRICA	13,049,098	207	259,515	-	248,923	484,058,451	398,811,838	66,003,692
AMERICAS	193,252,991	5,495	2,962,813	210	1,241,905	835,447,892	731,893,384	495,237,137
EUROPE	251,784,072	107,397	2,073,941	752	2,112,410	569,620,774	541,040,894	383,756,585
MIDDLE EAST	22,712,925	677	239,773	16	216,065	144,725,560	130,012,483	60,203,464
TOTAL	480,799,086	113,776	5,536,042	978	3,819,303	2,033,852,677	1,801,758,599	1,005,200,878


COVID-19 Epi curve among ASEAN Countries

From January 1, 2022 to February 23, 2023



COVID-19 Vaccination Status in ASEAN

as of 23 February 2023





ASEAN COVID-19 Outlook Assessment

as of 21 February 2023

ASEAN MEMBER STATE	immunity to COVID-19; eith 19 or have been vaccinate	population has a level of her recovered from COVID- ed with at least one dose of 9 vaccine.	Case levels are generally low (a 7-day rolling average number of daily new cases that is <10 cases per 100,000, with each day's past-14-day test positivity is consistently <5%).	Government Policy on containment and health (strictness and comprehensiveness in COVID-19 related government policies)	
	% of Total population ful	ly vaccinated / boosted	Daily cases/ 100,000	Containment and health index score - Oxford COVID-19 Government Response Tracker (OxCGRT)	
Brunei Darussalam	≥90.0	75.5	0.00	31.0/100	
Cambodia	≥90.0	62.2	0.01	31.5/100	
Indonesia	66.1	24.7	0.07	54.2/100	
Lao PDR	77.3	ND	0.02	61.6/100	
Malaysia	84.5	50.3	0.67	51.8/100	
Myanmar	52.1	4.1	0.01	69.1/100	
Philippines	71.6	18.5	0.10	55.4/100	
Singapore	≥90.0	78.8	0.00	58.9/100	
Thailand	77.7	44.8	0.04	31.5/100	
Vietnam	≥90.0	58.5	0.01	43.5/100	

All of the countries have achieved the Population vaccinated/ day (7-day average) except Vietnam.



Special Report on Notable Diseases

Avian Influenza H5N1


Cambodia: Feb 24 (Reuters) - Cambodia reported an 11-year-old girl from a province • east of the capital Phnom Penh died after being infected by the H5N1 strain of avian influenza, commonly known as bird flu.⁷ It was the first known human infection with the H5N1 strain in the Southeast Asian country since 2014, Minister of Health Mam Bunheng said in a statement on Feb 23.⁷ The girl from Prey Veng province was diagnosed with bird flu after falling sick with a high fever and cough on Feb. 16, the statement said.⁷ When her condition deteriorated, she was transferred to the National Children's Hospital in Phnom Penh for treatment, but died on Feb 22, the ministry of health said.⁷ Since early last year, bird flu has ravaged farms around the world, leading to the deaths of more than 200 million birds because of the disease or mass culls, the World Organization for Animal Health (WOAH) recently told Reuters.⁷ The World Health Organization (WHO) earlier this month noted the spread to mammals of H5N1 influenza, but said the risk to humans remained low.⁷ H5N1 had spread among poultry and wild birds for 25 years, WHO Director-General Tedros Adhanom Ghebreyesus told a briefing, but recent reports of infections in mink, otters and sealions "need to be monitored closely".⁷ Cambodian health authorities urged people not to handle dead or sick animals and birds, and to contact a hotline if anyone suspected they had been infected by the disease.⁷ [Full article]

Does bird flu pose a risk to humans?

From 2020 through 2022 there were only nine confirmed human cases, including one in the US and one in the UK, according to the World Health Organization.⁸ (One case was reported in Ecuador in January this year and another in Cambodia in February.⁸) Most often they involved a person who was in direct contact with sick birds.⁸ The viruses currently circulating do not have genetic changes that have been previously tied to infecting people more easily or causing severe illness, according to the CDC.⁸ For example, they cannot bind easily to human respiratory tract receptors.⁸ Even in an outbreak last year at a Spanish mink farm, where more than 50,000 animals were culled, there was no sign of infection among nearly a dozen workers.⁸ An expert report published by the European Food Safety Authority in January put the risk for the general population at low, as has the WHO, while urging continued close monitoring.⁸ [Full article]

Mpox (Monkeypox) Cases Reported Globally


as of February 18, 2023





Mpox Daily Trend Globally

as of February 18, 2023





Mpox: Highlights and Situation Overview

- As of 23 February 2023 (1PM, GMT+7), worldwide, there were **86,019** confirmed cases, including **96** deaths. Globally, Case Fatality Rate (CFR) was **0.11%**.
- **43 confirmed cases** in the ASEAN region, with CFR of **0%**.
- **85,976 confirmed cases** of Mpox have been reported in other **5 regions** (other than ASEAN region):

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Indonesia	1	-	-	0.00%
Philippines	4	-	-	0.00%
Singapore	21	-	-	0.00%
Thailand	15	-	-	0.00%
Vietnam	2	-	-	0.00%
ASEAN Total	43	-	-	0.00%

Mpox cases in ASEAN region

Mpox cases in Asia-Pacific region

Country/Territory	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Australia	144	-	-	0.00%
India	22	-	1	5.00%
Japan	20	-	-	0.00%
New Caledonia	1	-	-	0.00%
New Zealand	41	-	-	0.00%
People's Republic of China*	7	-	-	0.00%
Republic of Korea	4	-	-	0.00%
Sri Lanka	2	-	-	0.00%
Asia-Pacific Total	241	-	1	0.42%

*People's Republic of China – including Hongkong (SAR), Macao (SAR), and Taiwan (Province of China)

Top 5 countries with most mpox cases globally

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
United States of America	29,987	-	32	0.11%
Brazil	10,808	-	15	0.14%
Spain	7,538	-	3	0.04%
France	4,128	-	-	0.00%
Colombia	4,080	-	-	0.00%



REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	1,412	-	17	1.20%
AMERICAS	58,373	-	73	0.12%
ASEAN	43	-	-	0.00%
ASIA PACIFIC	241	-	1	0.41%
EUROPE	25,567	-	5	0.02%
MIDDLE EAST	320	-	-	0.00%
TOTAL	86,019	0	96	0.11%

Mpox cases per region

Research Update (Published and peer-reviewed studies)

In the study Mpox in people with advanced HIV infection: a global case series, clinicians have identified a severe, flesh-eating form of mpox with a 15% death rate in HIV patients who have suppressed immune systems according to a global case series.⁶ A network of clinicians from 19 countries evaluated 382 adult mpox patients who also had advanced HIV, including 27 of the 60 people globally who died by the end of the study on January 18, 2023.⁶ Participants included 367 cisgender men, 4 cisgender women, and 10 transgender women.⁶ The median participant age was 35 years.⁶ At mpox diagnoses, 349 (91%) of 382 participants had HIV, 228 of 349 (65%) were adherent to antiretroviral therapy (ART), and 32 of 382 (8%) also had an additional infection related to their suppressed immune system.⁶ Only 26 of the study participants (7%) had received the Jynneos mpox vaccine. Sixteen (4%) had been vaccinated before 2022, presumably for smallpox. Severe complications were more common in patients with a CD4 count less than 100 cells/mm³ than in those with more than 300 cells/mm³ and included necrotizing (flesheating) skin lesions (54% vs 7%), lung dysfunction sometimes accompanied by nodules (29% vs 0%), and secondary infections and sepsis (44% vs 9%).⁶ A total of 107 patients (28%) were hospitalized, and 27 (25%) of them died.⁶ All deaths were among patients with CD4 counts of less than 200 cells/mm3; most occurred in those with a high HIV viral load.⁶ The clinicians suspected an inflammatory immune reaction to mpox in 21 (25%) of 85 people who started or restarted on ART, 12 (57%) of whom died.⁶ Sixty-two of 382 patients (16%) received the Tpoxx smallpox/mpox drug (tecovirimat), and 7 (2%) were given other antivirals (cidofovir or brincidofovir).⁶ Three cases of tecovirimat resistance were identified.⁶ According to the lead author, a severe form of mpox affecting mostly young men who have sex with men resulted in death in 15% of people with advanced HIV.⁶ Thereby, health authorities should prioritize the vaccination of people living with HIV, particularly in countries with low levels of diagnosis or without universal free access to antiretroviral treatment.⁶ [Full text]

References

- 1. Portmann, Lea, et al. "Hospital Outcomes of Community-Acquired SARS-COV-2 Omicron Variant Infection Compared with Influenza Infection in Switzerland." JAMA Network Open, vol. 6, no. 2, 15 Feb. 2023, https://doi.org/10.1001/jamanetworkopen.2022.55599.
- Bart, Stephen M., et al. "Effect of Predeparture Testing on Postarrival SARS-COV-2–Positive Test Results among International Travelers — CDC Traveler-Based Genomic Surveillance Program, Four U.S. Airports, March–September 2022." MMWR. Morbidity and Mortality Weekly Report, vol. 72, no. 8, 24 Feb. 2023, pp. 206–209., https://doi.org/10.15585/mmwr.mm7208a2.
- 3. Luoma, Elizabeth, et al. "Notes from the Field: Epidemiologic Characteristics of SARS-COV-2 Recombinant Variant XBB.1.5 — New York City, November 1, 2022–January 4, 2023." *MMWR. Morbidity and Mortality Weekly Report*, vol. 72, no. 8, 24 Feb. 2023, pp. 212–214., https://doi.org/10.15585/mmwr.mm7208a4.
- 4. Morfino, Robert C., et al. "Notes from the Field: Aircraft Wastewater Surveillance for Early Detection of SARS-COV-2 Variants John F. Kennedy International Airport, New York City, August–September 2022." *MMWR. Morbidity and Mortality Weekly Report*, vol. 72, no. 8, 24 Feb. 2023, pp. 210–211., https://doi.org/10.15585/mmwr.mm7208a3.
- Mangat, Halinder S., et al. "Reported Rates of All-Cause Serious Adverse Events Following Immunization with BNT-162b in 5–17-Year-Old Children in the United States." *PLOS ONE*, vol. 18, no. 2, 17 Feb. 2023, https://doi.org/10.1371/journal.pone.0281993.
- 6. Mitjà, Oriol, et al. "Mpox in People with Advanced HIV Infection: A Global Case Series." The Lancet, 21 Feb. 2023, https://doi.org/10.1016/s0140-6736(23)00273-8.
- Davies, Ed. "Cambodia Tests More People for Bird Flu after Death of 11-Year-Old Girl." Edited by Jamie Freed and Martin Petty, *Reuters*, Thomson Reuters, 24 Feb. 2023, https://www.reuters.com/world/asia-pacific/cambodia-reports-death-11-year-old-girlbird-flu-2023-02-24/.
- 8. Cortez, Michelle Fay. "H5N1 Explainer: Bird Flu in Mammals Sparks Fear of Mutation Spreading to Humans." *Bloomberg.com*, Bloomberg, 24 Feb. 2023, https://www.bloomberg.com/news/articles/2023-02-24/h5n1-explainer-bird-flu-inmammals-sparks-fear-of-virus-spreading-in-humans.
- Villanueva, Rhodina. "Covid-19 Drugs out in Philippine Markets Soon." Philstar.com, Philstar.com, 23 Feb. 2023, https://www.philstar.com/headlines/2023/02/24/2247323/covid-19-drugs-out-philippinemarkets-soon.





Report generated by **ASEAN Biodiaspora Virtual Center (ABVC)** in collaboration with **Bluedot Inc.** *Email: support@biodiaspora.org* Facebook: <u>https://facebook.com/ASEANBiodiaspora</u> Instagram: <u>https://instagram.com/ASEANBiodiaspora</u>